The status of RAD50 can significantly affect a cancer patient's response to therapy. Tumors with defective RAD50 may exhibit sensitivity to DNA-damaging agents like radiation and certain chemotherapies, which rely on an intact DNA repair mechanism for cell survival. Conversely, tumors with upregulated RAD50 may be more resistant to these treatments, necessitating alternative therapeutic strategies.
